Much of the attention on Pfizer, BioNTech, Moderna, Johnson & Johnson and AstraZeneca has been on their Covid-19 vaccine efforts, and here is a look at what else is going on with these companies.
NeonMind Biosciences Inc., a psychedelic drug development company, announced the appointment of accomplished pharmaceutical executive Robert Tessarolo as President and Chief Executive Officer.
A bomb squad was called to a facility in the United Kingdom where doses of AstraZeneca’s Covid-19 vaccine are manufactured.
Vir Biotechnology, Eli Lilly and GlaxoSmithKline struck a three-way collaborative deal to evaluate Vir’s investigational monoclonal antibody VIR-7831 in combination with Lilly’s bamlanivimab in low-risk patients with mild to moderate Covid-19.
Sanofi will fill and pack millions of doses of Pfizer’s Covid-19 vaccine from July in an effort to help meet the huge demand for the U.S. drugmaker’s shots.
Findings from a Phase III long-term extension study show a once-daily therapy consisting of relugolix with estradiol and norethindrone acetate leads to clinically meaningful reductions in menstrual pain and non-menstrual pelvic pain over one year in women with endometriosis.
Ashfield, part of UDG Healthcare plc, announced the formation of three business units to bolster the company’s integrated healthcare services across strategic consulting, benchmarking, commercialization, customer engagement, events, marketing and communications.
Moderna started development on a booster to the company’s Covid-19 vaccine, which is hoped to work against the recently discovered (and more transmissible) SARS-CoV-2 variant from South Africa.
The U.S. Federal Trade Commission filed a lawsuit against Endo Pharmaceuticals and Impax Laboratories that alleges a 2017 agreement eliminated competition between the companies for the pain medicine oxymorphone ER.
A U.S. judge granted a Reuters request to unseal Merck & Co. documents produced in lawsuits related to the company’s anti-baldness treatment Propecia, finding that the public’s right to access outweighed the drug maker’s arguments for keeping the information secret.